Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 16.01 0.06% 0.01
HALO closed up 2.43 percent on Tuesday, January 15, 2019, on 68 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical HALO trend table...

Date Alert Name Type % Chg
Jan 15 180 Bullish Setup Bullish Swing Setup 0.06%
Jan 15 NR7 Range Contraction 0.06%
Jan 15 Upper Bollinger Band Walk Strength 0.06%
Jan 15 Inside Day Range Contraction 0.06%
Jan 15 Overbought Stochastic Strength 0.06%
Jan 14 Upper Bollinger Band Walk Strength 2.50%
Jan 14 Overbought Stochastic Strength 2.50%
Jan 14 Upper Bollinger Band Touch Strength 2.50%
Jan 11 MACD Bullish Centerline Cross Bullish -1.48%
Jan 11 Above Upper BB Strength -1.48%

Older signals for HALO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Is HALO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.48
52 Week Low 13.24
Average Volume 814,214
200-Day Moving Average 17.3572
50-Day Moving Average 15.3878
20-Day Moving Average 14.7705
10-Day Moving Average 15.276
Average True Range 0.7347
ADX 22.14
+DI 19.3622
-DI 16.642
Chandelier Exit (Long, 3 ATRs ) 14.1459
Chandelier Exit (Short, 3 ATRs ) 15.4441
Upper Bollinger Band 16.2732
Lower Bollinger Band 13.2678
Percent B (%b) 0.91
BandWidth 20.347314
MACD Line 0.1416
MACD Signal Line -0.0874
MACD Histogram 0.229
Fundamentals Value
Market Cap 2.14 Billion
Num Shares 134 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -17.20
Price-to-Sales 16.99
Price-to-Book 39.19
PEG Ratio -2.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.74
Resistance 3 (R3) 16.69 16.41 16.61
Resistance 2 (R2) 16.41 16.22 16.43 16.57
Resistance 1 (R1) 16.20 16.10 16.31 16.25 16.53
Pivot Point 15.92 15.92 15.97 15.94 15.92
Support 1 (S1) 15.71 15.73 15.82 15.76 15.47
Support 2 (S2) 15.43 15.61 15.45 15.43
Support 3 (S3) 15.22 15.43 15.39
Support 4 (S4) 15.27